ZURICH, July 14 An experimental drug from Roche
helped people with an advanced form of skin cancer live
longer without their disease worsening when used in combination
with another treatment, the Swiss drugmaker said on Monday.
The Basel-based firm was investigating cobimetinib, in
combination with another of its drugs called Zelboraf, as a
treatment for patients with tumours that have a mutation in a
gene known as BRAF that allows melanoma cells to grow.
Results of a late-stage study found taking the two therapies
together helped patients live significantly longer without their
disease worsening compared to Zelboraf alone, meeting the
study's main goal.
(Reporting by Caroline Copley; Editing by Ron Popeski)